Skip to content
Screener

Bausch + Lomb BLCO Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

HRO
HarrowHROW
$50.84M+259%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$2.12M+83.3%
PBH
Prestige Consumer HealthcarePBH
$299.14M+6.6%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
AbbVie logo
AbbVieABBV
Bausch Health Companies logo
Bausch Health CompaniesBHC

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.99B+24.2%
Enterprise value$10.69B+12.4%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
(in millions)June 30, 2026 / Gross Carrying AmountJune 30, 2026 / Accumulated Amortization and ImpairmentsJune 30, 2026 / Net Carrying AmountDecember 31, 2025 / Gross Carrying AmountDecember 31, 2025 / Accumulated Amortization and ImpairmentsDecember 31, 2025 / Net Carrying Amount
Product brands$4,386$(3,114)$1,272$4,441$(3,064)$1,377
Corporate brands103(31)72102(26)76
Product rights/patents998(988)10999(988)11
Other87(70)1787(68)19
Total finite-lived intangible assets5,574(4,203)1,3715,629(4,146)1,483
Acquired in-process research and development intangible asset100100100100
B&L Trademark1,6981,6981,6981,698
$7,372$(4,203)$3,169$7,427$(4,146)$3,281

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's finite-lived intangible assets, accumulated amortization?
Bausch + Lomb (BLCO) reported finite-lived intangible assets, accumulated amortization of $4.2B in Q2 2026.
How has Bausch + Lomb's finite-lived intangible assets, accumulated amortization changed year-over-year?
Bausch + Lomb's finite-lived intangible assets, accumulated amortization increased by 4.5% year-over-year, from $4.02B to $4.2B.
What is the long-term trend for Bausch + Lomb's finite-lived intangible assets, accumulated amortization?
Over 4 years (2021 to 2025), Bausch + Lomb's finite-lived intangible assets, accumulated amortization has grown at a 7.0% compound annual growth rate (CAGR), from $3.16B to $4.15B.

Ask your AI about Bausch + Lomb's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude